Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536245 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL16729598 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL1549880 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL16059514 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL8806728 | 0.86 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL8064199 | 0.86 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL376575 | 0.86 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL9386815 | 0.86 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL3243612 | 0.86 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL21311371 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM3GPR119HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2313395-B1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | CHRM2 37/4885CHRM1 48/4885CHRM3 77/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | CHRM2 40/4885CHRM1 53/4885CHRM3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.